Atossa Genetics Inc Share Price Nasdaq
Equities
US04962H1005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
02/07 | Atossa Therapeutics Names Heather Rees CFO | MT |
02/07 | Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 147M 12.29B |
---|---|---|---|---|---|
Net income 2024 * | -30M -2.51B | Net income 2025 * | -35M -2.92B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.88
x | P/E ratio 2025 * |
-4.25
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Atossa Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01/08/01 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01/08/01 |
Heather Rees
DFI | Director of Finance/CFO | 51 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01/08/01 |
Director/Board Member | 66 | 01/14/01 | |
H. Remmel
BRD | Director/Board Member | 72 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
-10.62% | 37.68B | |
+40.49% | 39.84B | |
+29.92% | 31.46B | |
-9.78% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |